Exploiting HPV-Induced Carcinogenesis for a Rational Drug Development in Cervical Cancer

Página do item simplificado
dc.creatorAngélica Nogueira Rodrigues
dc.creatorAndréia Cristina Melo
dc.creatorGustavo Werutsky
dc.creatorAlvaro H. I. Garces
dc.creatorCarlos Gil Moreira Ferreira
dc.date.accessioned2023-08-10T20:59:48Z
dc.date.accessioned2025-09-09T01:09:58Z
dc.date.available2023-08-10T20:59:48Z
dc.date.issued2016
dc.format.mimetypepdf
dc.identifier.doi10.2174/1568009616666151118115018
dc.identifier.issn1568-0096
dc.identifier.urihttps://hdl.handle.net/1843/57715
dc.languageeng
dc.publisherUniversidade Federal de Minas Gerais
dc.relation.ispartofCurrent Cancer Drug Targets
dc.rightsAcesso Restrito
dc.subjectCâncer de colo de útero
dc.subjectCarcinogênese
dc.subjectPapillomavirus Humano
dc.subject.otherCâncer
dc.subject.otherCarcinogênese
dc.subject.otherCâncer de colo de útero
dc.subject.otherPapiloma Vírus Humano (HPV)
dc.subject.otherTerapias direcionadas
dc.titleExploiting HPV-Induced Carcinogenesis for a Rational Drug Development in Cervical Cancer
dc.typeArtigo de periódico
local.citation.epage260
local.citation.issue3
local.citation.spage249
local.citation.volume16
local.description.resumoAbstract: Cervical carcinomas are almost universally associated with high-risk human papillomavirus (HPV) infections, and are a leading cause of cancer death in women worldwide. Since the late 1990s, when a spate of studies reported the benefit of cisplatin-based chemotherapy, there had been a dearth of clinical trials in cervical cancer (CC). More effective therapies in locally advanced and recurrent or metastatic CC are an urgent clinical need. In the era of molecular oncology one should look beyond conventional chemoradiation and chemotherapy for locally advanced and advanced CC. The fact that the initiating oncogenic insult, infection with a high-risk HPV and viral oncoprotein expression is common to almost all CC offers unique opportunities for disease control. Diverse biologic pathways with an implication in the development and progression of CC are being explored. For the first time, increase in overall survival has recently been obtained for advanced CC patients with a target drug, the antiangiogenic agent bevacizumab, and durable complete responses after HPV-targeted adoptive T cell therapy in metastatic CC patients were achieved. In this review, we will summarize molecular aspects of HPV infection focusing on potential targets to stop the carcinogenic process, present updated drug development data, and discuss challenges and prospects for the future.
local.publisher.countryBrasil
local.publisher.departmentMED - DEPARTAMENTO DE CLÍNICA MÉDICA
local.publisher.initialsUFMG
local.url.externahttps://www.eurekaselect.com/article/71924

Arquivos

Licença do pacote

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
License.txt
Tamanho:
1.99 KB
Formato:
Plain Text
Descrição:
Baixar

Coleções

Artigo de Periódico

Logo UFMG